Search Results for: FGFR1

Novel Interactant Symbol Name
Associated Pathways
Binding Drugs
Associated Diseases
FGF18 fibroblast growth factor 18
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
FGF2 fibroblast growth factor 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR1b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR2b ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
  • Syndecan interactions
  • Non-integrin membrane-ECM interactions
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • Interleukin-4 and Interleukin-13 signaling
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR2 IIIa TM
  • Signaling by FGFR3 point mutants in cancer
  • Sucralfate
  • Pentosan polysulfate
  • Sirolimus
  • Heparin
  • 1,4-Dideoxy-O2-Sulfo-Glucuronic Acid
  • N,O6-Disulfo-Glucosamine
  • 1,4-Dideoxy-5-Dehydro-O2-Sulfo-Glucuronic Acid
  • ABT-510
FGF3 fibroblast growth factor 3
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR1b ligand binding and activation
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Kaposi's sarcoma
FGF4 fibroblast growth factor 4
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • FGFRL1 modulation of FGFR1 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
  • Pentosan polysulfate
  • Heparin
  • TP-508
FGF5 fibroblast growth factor 5
FGF6 fibroblast growth factor 6
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • FGFR4 ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
FGF7 fibroblast growth factor 7
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • FGFR2b ligand binding and activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR2
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • Negative regulation of FGFR2 signaling
  • Signaling by FGFR2 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
FGF8 fibroblast growth factor 8
  • Hypogonadotropic hypogonadism; Kallmann syndrome (KAL)
FGF9 fibroblast growth factor 9
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Signaling by activated point mutants of FGFR1
  • Signaling by activated point mutants of FGFR3
  • FGFR4 ligand binding and activation
  • FGFR3b ligand binding and activation
  • FGFR3c ligand binding and activation
  • FGFR1c ligand binding and activation
  • FGFR2c ligand binding and activation
  • FGFR3 mutant receptor activation
  • Activated point mutants of FGFR2
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade: FGFR1
  • Phospholipase C-mediated cascade; FGFR2
  • Phospholipase C-mediated cascade; FGFR3
  • Phospholipase C-mediated cascade; FGFR4
  • Downstream signaling of activated FGFR1
  • SHC-mediated cascade:FGFR1
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • SHC-mediated cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • SHC-mediated cascade:FGFR3
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 point mutants in cancer
  • Transcriptional regulation of testis differentiation
FLRT3 fibronectin leucine rich transmembrane protein 3
  • Signaling by ROBO receptors
  • Downstream signaling of activated FGFR1
FRS2 fibroblast growth factor receptor substrate 2
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • Frs2-mediated activation
  • Frs2-mediated activation
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • PI-3K cascade:FGFR1
  • FRS-mediated FGFR1 signaling
  • PI-3K cascade:FGFR2
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • PI-3K cascade:FGFR3
  • FRS-mediated FGFR4 signaling
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR1 signaling
  • Negative regulation of FGFR2 signaling
  • Negative regulation of FGFR3 signaling
  • Negative regulation of FGFR4 signaling
  • Signaling by FGFR2 in disease
  • Signaling by FGFR4 in disease
  • Signaling by FGFR1 in disease
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
  • Signaling by FGFR3 fusions in cancer
  • Signaling by FGFR3 point mutants in cancer
  • RET signaling
  • Activated NTRK2 signals through FRS2 and FRS3
  • Activated NTRK2 signals through FRS2 and FRS3
FRS3 fibroblast growth factor receptor substrate 3
  • FRS-mediated FGFR1 signaling
  • FRS-mediated FGFR2 signaling
  • FRS-mediated FGFR3 signaling
  • FRS-mediated FGFR4 signaling
  • RAF/MAP kinase cascade
  • Activated NTRK2 signals through FRS2 and FRS3
GRB14 growth factor receptor bound protein 14
  • Tie2 Signaling
GRB2 growth factor receptor bound protein 2
  • Interleukin-15 signaling
  • Interleukin-15 signaling
  • STAT5 activation downstream of FLT3 ITD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Signaling by FLT3 ITD and TKD mutants
  • Pegademase
  • 4-[(10s,14s,18s)-18-(2-Amino-2-Oxoethyl)-14-(1-Naphthylmethyl)-8,17,20-Trioxo-7,16,19-Triazaspiro[5.14]Icos-11-En-10-Yl]Benzylphosphonic Acid
HTR1A 5-hydroxytryptamine receptor 1A
  • Serotonin receptors
  • Eletriptan
  • Ziprasidone
  • Methysergide
  • Cabergoline
  • Zolmitriptan
  • Amitriptyline
  • Olanzapine
  • Clozapine
  • Loxapine
  • Pramipexole
  • Methylphenidate
  • Imipramine
  • Chlorpromazine
  • Buspirone
  • Haloperidol
  • Nortriptyline
  • Amoxapine
  • Propranolol
  • Fenfluramine
  • Lisuride
  • Trazodone
  • Sumatriptan
  • Ergotamine
  • Apomorphine
  • Paroxetine
  • Trimipramine
  • Risperidone
  • Alprenolol
  • Ondansetron
  • Naratriptan
  • Pindolol
  • Dopamine
  • Ergoloid mesylate
  • Doxepin
  • Nefazodone
  • Desipramine
  • Escitalopram
  • Pergolide
  • Bromocriptine
  • Ketamine
  • Quetiapine
  • Aripiprazole
  • Chlorprothixene
  • Paliperidone
  • Penbutolol
  • Yohimbine
  • Acepromazine
  • Alverine
  • Molindone
  • Pipotiazine
  • Thioproperazine
  • Lysergic acid diethylamide
  • Dapoxetine
  • Bifeprunox
  • Flibanserin
  • Iloperidone
  • Lofexidine
  • Lesopitron
  • Rotigotine
  • MN-305
  • LI-301
  • Naluzotan
  • Cariprazine
  • Mianserin
  • Pizotifen
  • Asenapine
  • Xaliproden
  • Dotarizine
  • Sarizotan
  • Repinotan
  • Robalzotan
  • Vilazodone
  • Bopindolol
  • Cinitapride
  • Lurasidone
  • Perospirone
  • Cannabidiol
  • Vortioxetine
  • Brexpiprazole
  • Dosulepin
  • Pirlindole
  • Tianeptine
  • Setiptiline
  • Dihydroergocornine
  • Tetrahydrocannabivarin
  • Pardoprunox
  • Gilteritinib
  • Tiapride
  • Dihydroergocristine
  • Medical Cannabis
  • 5-methoxy-N,N-dimethyltryptamine
  • Nabiximols
  • Aripiprazole lauroxil
  • SEP-363856
HULC hepatocellular carcinoma up-regulated long non-coding RNA
IL17RD interleukin 17 receptor D
  • MAP2K and MAPK activation
ITGB3 integrin subunit beta 3
  • Platelet degranulation
  • Elastic fibre formation
  • PECAM1 interactions
  • Molecules associated with elastic fibres
  • Integrin cell surface interactions
  • Integrin cell surface interactions
  • Syndecan interactions
  • Syndecan interactions
  • ECM proteoglycans
  • Integrin signaling
  • GRB2:SOS provides linkage to MAPK signaling for Integrins
  • p130Cas linkage to MAPK signaling for integrins
  • VEGFA-VEGFR2 Pathway
  • Signal transduction by L1
  • MAP2K and MAPK activation
  • Signaling by moderate kinase activity BRAF mutants
  • Signaling by high-kinase activity BRAF mutants
  • Signaling by BRAF and RAF fusions
  • Paradoxical activation of RAF signaling by kinase inactive BRAF
  • Signaling downstream of RAS mutants
  • Signaling by RAF1 mutants
  • Abciximab
  • Eptifibatide
  • Antithymocyte immunoglobulin (rabbit)
  • Levothyroxine
  • Tirofiban
  • Resveratrol
  • Lefradafiban
  • LM-609
  • Fradafiban
  • Ferric maltol
  • Glanzmann thrombasthenia
  • Allograft rejection
ITK IL2 inducible T cell kinase
  • Generation of second messenger molecules
  • FCERI mediated Ca+2 mobilization
  • FCERI mediated Ca+2 mobilization
  • Staurosporine
  • Pazopanib
  • Fostamatinib
  • Zanubrutinib
KLB klotho beta
  • PI3K Cascade
  • PIP3 activates AKT signaling
  • betaKlotho-mediated ligand binding
  • Constitutive Signaling by Aberrant PI3K in Cancer
  • Phospholipase C-mediated cascade; FGFR4
  • FRS-mediated FGFR4 signaling
  • SHC-mediated cascade:FGFR4
  • PI-3K cascade:FGFR4
  • Negative regulation of FGFR4 signaling
  • RAF/MAP kinase cascade
  • PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling

Page 2 out of 4 pages